Cargando…
Halogenated Flavonoid Derivatives Display Antiangiogenic Activity
Antiangiogenic agents attenuate tumours’ growth and metastases and are therefore beneficial as an adjuvant or standalone cancer regimen. Drugs with dual antiproliferative and antiangiogenic activities can achieve anticancer efficacy and overcome acquired resistance. In this study, synthetic flavones...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331694/ https://www.ncbi.nlm.nih.gov/pubmed/35897938 http://dx.doi.org/10.3390/molecules27154757 |
_version_ | 1784758463499337728 |
---|---|
author | Khater, Mai Watson, Kimberly A. Boateng, Samuel Y. Greco, Francesca Osborn, Helen M. I. |
author_facet | Khater, Mai Watson, Kimberly A. Boateng, Samuel Y. Greco, Francesca Osborn, Helen M. I. |
author_sort | Khater, Mai |
collection | PubMed |
description | Antiangiogenic agents attenuate tumours’ growth and metastases and are therefore beneficial as an adjuvant or standalone cancer regimen. Drugs with dual antiproliferative and antiangiogenic activities can achieve anticancer efficacy and overcome acquired resistance. In this study, synthetic flavones (5a,b) with reported anticancer activity, and derivatives (4b and 6a), exhibited significant inhibition of endothelial cell tube formation (40–55%, 12 h) at 1 µM, which is comparable to sunitinib (50% inhibition at 1 µM, 48 h). Flavones (4b, 5a,b and 6a) also showed 25–37% reduction in HUVECs migration at 10 µM. In a Western blotting assay, 5a and 5b subdued VEGFR2 phosphorylation by 37% and 57%, respectively, suggesting that VEGFR2 may be their main antiangiogenic target. 5b displayed the best docking fit with VEGFR2 in an in silico study, followed by 5a, emphasizing the importance of the 7-hydroxyl group accompanied by a 4−C=S for activity. Conversely, derivatives with a 4-carbonyl moiety fitted poorly into the target’s binding pocket, suggesting that their antiangiogenic activity depends on a different target. This study provides valuable insight into the Structure Activity Relationships (SAR) and modes of action of halogenated flavones with VEGFR2 and highlights their therapeutic potential as antiangiogenic/anticancer lead compounds. |
format | Online Article Text |
id | pubmed-9331694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93316942022-07-29 Halogenated Flavonoid Derivatives Display Antiangiogenic Activity Khater, Mai Watson, Kimberly A. Boateng, Samuel Y. Greco, Francesca Osborn, Helen M. I. Molecules Article Antiangiogenic agents attenuate tumours’ growth and metastases and are therefore beneficial as an adjuvant or standalone cancer regimen. Drugs with dual antiproliferative and antiangiogenic activities can achieve anticancer efficacy and overcome acquired resistance. In this study, synthetic flavones (5a,b) with reported anticancer activity, and derivatives (4b and 6a), exhibited significant inhibition of endothelial cell tube formation (40–55%, 12 h) at 1 µM, which is comparable to sunitinib (50% inhibition at 1 µM, 48 h). Flavones (4b, 5a,b and 6a) also showed 25–37% reduction in HUVECs migration at 10 µM. In a Western blotting assay, 5a and 5b subdued VEGFR2 phosphorylation by 37% and 57%, respectively, suggesting that VEGFR2 may be their main antiangiogenic target. 5b displayed the best docking fit with VEGFR2 in an in silico study, followed by 5a, emphasizing the importance of the 7-hydroxyl group accompanied by a 4−C=S for activity. Conversely, derivatives with a 4-carbonyl moiety fitted poorly into the target’s binding pocket, suggesting that their antiangiogenic activity depends on a different target. This study provides valuable insight into the Structure Activity Relationships (SAR) and modes of action of halogenated flavones with VEGFR2 and highlights their therapeutic potential as antiangiogenic/anticancer lead compounds. MDPI 2022-07-25 /pmc/articles/PMC9331694/ /pubmed/35897938 http://dx.doi.org/10.3390/molecules27154757 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Khater, Mai Watson, Kimberly A. Boateng, Samuel Y. Greco, Francesca Osborn, Helen M. I. Halogenated Flavonoid Derivatives Display Antiangiogenic Activity |
title | Halogenated Flavonoid Derivatives Display Antiangiogenic Activity |
title_full | Halogenated Flavonoid Derivatives Display Antiangiogenic Activity |
title_fullStr | Halogenated Flavonoid Derivatives Display Antiangiogenic Activity |
title_full_unstemmed | Halogenated Flavonoid Derivatives Display Antiangiogenic Activity |
title_short | Halogenated Flavonoid Derivatives Display Antiangiogenic Activity |
title_sort | halogenated flavonoid derivatives display antiangiogenic activity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331694/ https://www.ncbi.nlm.nih.gov/pubmed/35897938 http://dx.doi.org/10.3390/molecules27154757 |
work_keys_str_mv | AT khatermai halogenatedflavonoidderivativesdisplayantiangiogenicactivity AT watsonkimberlya halogenatedflavonoidderivativesdisplayantiangiogenicactivity AT boatengsamuely halogenatedflavonoidderivativesdisplayantiangiogenicactivity AT grecofrancesca halogenatedflavonoidderivativesdisplayantiangiogenicactivity AT osbornhelenmi halogenatedflavonoidderivativesdisplayantiangiogenicactivity |